May. 12 at 5:40 PM
$XLO @809trader So, perhaps they get another
$60 Million in the next few months?
"This estimate excludes any potential additional milestone payments, option-related fees or other contingent payments under Xilio’s collaboration and license agreements with AbbVie and Gilead and excludes up to
$36.2 million in additional gross proceeds in the second half of 2026 if all outstanding Series C warrants are exercised at their current exercise price.
Xilio has the potential to achieve up to
$31.0 million in additional near-term milestones and option extension fees under the existing AbbVie collaboration through the first half of 2027."
